首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1695957

全球 LAG-3 標靶治療市場：劑量、專利、銷售和臨床試驗洞察（2030 年）

Global LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030

出版日期: 2025年04月01日 | 出版商:

KuicK Research | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，LAG-3 標靶治療的全球市場價值將超過 40 億美元。

LAG-3標靶治療在全球市場受到關注，因為它在治療癌症、自體免疫疾病和發炎性疾病等多種疾病方面具有潛在的應用。一種稱為淋巴細胞活化基因 3 (LAG-3) 的免疫檢查點受體對於控制免疫反應至關重要。因此，已經開發出多種治療方法來改變 LAG-3 活性，透過活化、消耗或抑制它，每種方法都有獨特的治療應用。其中最受歡迎的策略是 LAG-3 抑制，但 Immutep 開發的 LAG-3 活化和消耗也越來越流行。

在這個市場中，LAG-3 抑制仍然是最受歡迎的治療策略，因為它旨在提高免疫系統識別和消除癌細胞的能力。這種方法主要使用單株抗體。此單株抗體旨在阻斷 LAG-3 受體，有效地最大限度地發揮 T 細胞對腫瘤細胞的攻擊作用。 ZGGS-15 等同時針對 TIGIT 和 LAG-3 的雙特異性抗體是未來的創新療法。蘇州澤璟生物製藥的ZGGS-15專門用於治療實體腫瘤。雙特異性抗體有可能透過同時針對兩個免疫檢查點路徑來增強免疫療法的療效。

除了癌症之外，研究人員還在研究如何利用 LAG-3 來治療自體免疫疾病和發炎疾病。儘管該研究領域仍處於早期階段，但越來越多的證據表明，調節 LAG-3 可能對微生物疾病具有治療價值。 LAG-3抑制被認為是克服腫瘤引起的免疫抑制的一種手段。

Opdualag 是抗 PD-1 單株抗體 nivolumab 與抗 LAG-3 單株抗體 leratolimab 的組合，是該領域的重要成功案例。 Opduralag 於 2022 年獲批，預計當年銷售額將超過 2.5 億美元，2024 年將達到 9 億美元。這一令人印象深刻的擴張預示著類似療法的光明前景，也反映出 LAG-3 標靶療法在腫瘤市場越來越受到認可。

目前，超過 35 個 LAG-3 標靶候選藥物正在臨床開發中，這表明人們對該領域的廣泛興趣和持續創新。再生元製藥憑藉其主要候選藥物之一 fianlimab 已成為該市場的主要參與者。目前，fianlimab 正處於 3 期試驗階段，正在針對多種癌症適應症進行評估，並有可能對治療前景產生重大影響。 Immutep 的 IMP-761 是一流的 LAG-3 激動劑，也是一個令人興奮的候選藥物。 IMP-761 目前正在早期人體臨床試驗中進行安全性和有效性測試，隨後將擴大用於治療自體免疫疾病。

因此，LAG-3 標靶治療的臨床試驗數量的增加和適應症的擴大表明該市場在未來幾年將實現顯著增長。單株抗體和雙特異性抗體的融合，加上對 LAG-3 激動和消耗的持續追求，提供了廣泛的治療方法，可能會徹底改變癌症、自體免疫疾病等的治療。隨著研究的進展，LAG-3標靶治療預計將在免疫腫瘤學和其他免疫相關疾病中變得越來越不可或缺，從而推動市場的進一步成長。

本報告研究了全球 LAG-3 標靶治療市場，並概述了市場以及藥物趨勢、臨床試驗趨勢、區域趨勢以及參與市場的公司的競爭格局。

Global LAG-3 Targeting Therapies Market Opportunity By 2030: > USD 4 Billion
Global & Regional Market Insight
Approved Drug Global & Regional Sales Analysis
Approved LAG-3 Drug Dosing, Pricing & Sales Insight
Global LAG3 Inhibitors clinical Trials Insight By Company, Country, Indication and Phase
Insight On More Than 35 LAG-3 Targeted Therapies In Clinical Trials
Expected Completion Time For Key Drugs In Clinical Trials

The potential of LAG-3 targeting therapy to treat a number of ailments, particularly cancer, autoimmune diseases, and inflammatory diseases, has attracted a lot of attention to the global market. An immune checkpoint receptor called lymphocyte-activation gene 3 (LAG-3) is essential for controlling immune responses. As a result, a number of treatments have been developed to modify LAG-3 activity, either by activation, depletion, or inhibition, each with unique therapeutic uses. The most popular strategy among them is LAG-3 inhibition, but LAG-3 activation and depletion, both of which were developed by Immutep, are also becoming more popular.

In this market, LAG-3 inhibition is still the most popular therapeutic strategy because it aims to improve the immune system's capacity to recognize and eliminate cancer cells. The approach primarily involves the use of monoclonal antibodies, which are intended to inhibit the LAG-3 receptor, effectively maximizing T-cells to attack tumor cells. Bispecific antibodies, such as ZGGS-15, which targets both TIGIT and LAG-3, represent an upcoming and innovative class of therapies. Suzhou Zelgen Biopharmaceuticals' ZGGS-15 is specifically designed to treat solid tumors. Bispecific antibodies have the potential to increase the effectiveness of immune therapies by simultaneously targeting two immune checkpoint pathways, particularly for complex conditions like solid tumors that are typically more difficult to treat.

In addition to cancer, researchers are also looking into how LAG-3 targeting might be used to treat autoimmune and inflammatory disorders. Although research in this area is still in its early stages, there is also mounting evidence that suggests LAG-3 modulation may have therapeutic benefits in microbial diseases. The main focus, however, is still on cancer treatment, especially in the context of immunotherapy, where LAG-3 inhibition is thought to be a means of overcoming immune suppression brought on by tumors.

The drug Opdualag, which combines the anti-PD-1 monoclonal antibody nivolumab with the anti-LAG-3 monoclonal antibody relatlimab, is a significant success story in this field. Approved in 2022, Opdualag's revenue surpassed US$ 250 million that year, and in 2024, it exceeded US$ 900 million. This remarkable expansion indicates a promising future for similar treatments and reflects the growing acceptance of LAG-3 targeting therapies in the oncology market.

More than 35 LAG-3 targeting candidates are presently undergoing clinical development, demonstrating the expansive interest and continuous innovation in this area. Regeneron Pharmaceuticals is a major player in this market thanks to Fianlimab, one of its lead candidates. Fianlimab, which is presently undergoing Phase 3 trials, is being evaluated for a number of cancer indications and could have considerable effects on the treatment environment. Immutep's IMP-761, a first-in-class LAG-3 agonist, is another exciting candidate. IMP-761 is being tested for safety and effectiveness in humans in early phase trials, after which, the treatment will be expanded to autoimmune disorders.

Thus, the increasing number of clinical trials and the expanding therapeutic indications for LAG-3 targeting therapies indicate this market is positioned for substantial growth in the coming years. The amalgamation of monoclonal and bispecific antibodies, along with the ongoing pursuit of LAG-3 agonism and depletion, presents a wide array of potential treatments that could revolutionize the management of cancer, autoimmune diseases, and beyond. LAG-3 targeted therapies are anticipated to become increasingly essential in immuno-oncology and other immune-related disorders as research advances, propelling additional market growth.

1. Introduction to LAG-3 Targeting Therapies

1.1 LAG-3 As Therapeutic Target
1.2 LAG-3 Targeting Therapies - Mechanism Of Action
1.3 LAG-3 Targeting Approaches

2. Combination Strategies For LAG-3 Targeting Therapies

3. Global LAG-3 Targeting Therapy Market Scenario

3.1 Current Market Outlook
3.2 Future Market Outlook

4. LAG-3 Targeting Therapy Market Regional Analysis

4.1 US
4.2 EU
4.3 China
4.4 Australia
4.5 UK
4.6 Japan
4.7 Canada
4.8 South Korea

5. LAG-3 Targeting Therapy - Development Trends By Indication

5.1 Cancer
- 5.1.1 Lymphoma
- 5.1.2 Melanoma
- 5.1.3 Lung Cancer
- 5.1.4 Gastrointestinal Cancers
- 5.1.5 Head & Neck Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Microbial Infections

6. Opdualag (Nivolumab & Relatlimab) - Overview, Pricing, Dosing & Sales Analysis

6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight

7. Global LAG-3 Targeting Therapies Clinical Trials Overview

7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
7.6 Patient Segment

8. Global LAG3 Targeting Therapies clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III

9. Marketed LAG-3 Inhibitor Clinical Insight

10. Global LAG-3 Targeting Therapy Market Dynamics

10.1 Market Drivers
10.2 Market Challenges

11. Competitive Landscape

11.1 ABL Bio
11.2 Agenus
11.3 Akeso Biopharma
11.4 Bristol-Myers Squibb
11.5 EpimAb Biotherapeutics
11.6 F-star Therapeutics
11.7 Immutep
11.8 Innovent Biologics
11.9 Shanghai Henlius Biotech
11.10 Y-Biologics

簡介目錄圖表

List of Figures

Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 1-3: LAG-3 Inhibitor - Mechanism Of Action
Figure 1-4: LAG-3 Agonist - Mechanism Of Action
Figure 1-5: LAG-3 Depletion - Mechanism Of Action
Figure 1-6: Bispecific Antibodies - Binding Efficacy
Figure 2-1: Overview to LAG-3 Combinations
Figure 3-1: Global - LAG 3 Targeting Therapy Market Value (US$ Million), 2022-2024
Figure 3-2: Global - LAG 3 Targeting Therapy Market Value By Region (US$ Million), 2024
Figure 3-3: Global - LAG 3 Targeting Therapy Market Value By Region (%), 2024
Figure 3-4: Global - Quarterly LAG 3 Targeting Therapy Market Value (US$ Million), 2024
Figure 3-5: Global - LAG 3 Targeting Therapy Market Forecast (US$ Million), 2025 - 2030
Figure 3-6: Global LAG-3 Targeting Therapy Market - Future Outlook
Figure 4-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials
Figure 5-1: RELATIVITY-069 Phase 1/2 (NCT05255601) Study - Initiation & Completion Year
Figure 5-2: AK129-102 Phase 1/2 (NCT06642792) Study - Initiation & Completion Year
Figure 5-3: R3767-ONC-2011 Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-4: R3767-ONC-2055 Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-5: INCAGN 2385-201 Phase 1/2 (NCT04370704) Study - Initiation & Completion Year
Figure 5-6: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study - Initiation & Completion Year
Figure 5-7: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study - Initiation & Completion Year
Figure 5-8: R2810-ONC-1866 Phase 2 (NCT03916627) Study - Initiation & Completion Year
Figure 5-9: R2810-ONC-2266 Phase 2 (NCT06161441) Study - Initiation & Completion Year
Figure 5-10: RELATIVITY-104 Phase 2 (NCT04623775) Study - Initiation & Completion Year
Figure 5-11: RELATIVITY-1093 Phase 3 (NCT06561386) Study - Initiation & Completion Year
Figure 5-12: J23155 Phase 2 (NCT06205836) Study - Initiation & Completion Year
Figure 5-13: J1714 Phase 1b (NCT03044613) Study - Initiation & Completion Year
Figure 5-14: RELATIVITY-123 Phase 3 (NCT05328908) Study - Initiation & Completion Year
Figure 5-15: NP41300 Phase 1/2 (NCT04140500) Study - Initiation & Completion Year
Figure 5-16: LBL-007-CN-003 Phase 1b/2 (NCT05102006) Study - Initiation & Completion Year
Figure 5-17: HCC 18-139 Phase 2 (NCT04080804) Study - Initiation & Completion Year
Figure 5-18: IMP761-P001 Phase 1 (NCT06637865) Study - Initiation & Completion Year
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US - Cost Per Unit & Supply Of Opdualag (US$), April'2025
Figure 6-4: Cost Per Unit & Supply Of Opdualag (US$), April'2025
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2024
Figure 6-6: Global - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 6-7: Opdualag - US v/s ROW Sales (US$ Million), 2024
Figure 6-8: Global - Opdualag Sales (US$ Million), 2024
Figure 6-9: US - Opdualag Sales (US$ Million), 2022-2024
Figure 6-10: US - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 6-11: ROW - Opdualag Sales (US$ Million), 2022-2024
Figure 6-12: ROW - Opdualag Sales (US$ Million), Q1-Q4'2024
Figure 7-1: Global - LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2025 - 2030
Figure 7-2: Global - LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2025 - 2030
Figure 7-3: Global - LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2025 - 2030
Figure 7-4: Global - LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2025 - 2030
Figure 7-5: Global - LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2025 - 2030
Figure 7-6: Global - LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2025 - 2030
Figure 10-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 10-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints

List of Tables

Table 2-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors, April'2025
Table 4-1: US - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April'2025
Table 4-2: China - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April'2025
Table 4-3: Immutep - Active Patents By Region
Table 5-1: Melanoma - Some Ongoing Clinical Trials For LAG-3 Inhibitors, April'2025
Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges By Patient Group 1
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions

02-2729-4219

+886-2-2729-4219